Beyond 70,000: Reassessing the Global Fontan Population Through Citation-Chain Analysis and Tiered Epidemiologic Estimation
This study reveals that the widely cited global Fontan population estimate of 50,000–70,000 lacks any methodological basis, and proposes a transparent, tiered framework suggesting the true number is significantly higher (approximately 105,000–176,000) to provide reliable denominators for research and health policy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For children born with a single pumping chamber instead of the usual two, life depends on a series of delicate surgeries that rewire the heart's circulation. The final step in this journey is a procedure known as the Fontan operation, which reroutes blood so it flows directly to the lungs without passing through the heart's main pump. This surgery does not cure the condition, but it allows children to grow into adults, creating a unique and growing community of survivors who live with a modified circulatory system. As this population ages, doctors, researchers, and policymakers need to know exactly how many people are living with this condition to plan for their future care, fund new treatments, and design clinical trials. Without an accurate count, the needs of these patients remain invisible to the systems meant to support them.
For decades, the medical world has relied on a single number to describe the size of this global population: between 50,000 and 70,000 people. This figure appears in major medical guidelines, pharmaceutical filings, and grant applications, serving as the foundation for decisions about how much money and attention should be directed toward Fontan-related research. However, a new analysis reveals that this number has no solid foundation. The researchers behind this study traced the history of the estimate and found that it never originated from a scientific calculation or a global survey. Instead, the number entered the literature as an informal guess, attributed to unnamed experts in an editorial, and was then repeated by other authorities who cited the editorial rather than the original data. The chain of citations eventually loops back on itself, with every source pointing to another source that also lacks the original calculation. The number 70,000 was never peer-reviewed as a population estimate; it simply became accepted as fact because it was repeated often enough.
To replace this unverified figure, the author constructed a new way of counting that relies on available data rather than inherited assumptions. The study breaks the problem into three layers based on how much information exists for different parts of the world. For wealthy nations with established medical registries, the analysis uses verified counts and statistical models to estimate the number of survivors. For other high-income countries without specific registries, it applies rates from similar nations. For the rest of the world, where data is sparse, the study uses conservative estimates based on the few available reports from hospitals in those regions. When these layers are combined, the result is a much larger population than previously thought. The analysis suggests that there are likely between 83,000 and 94,000 Fontan survivors in high-income countries alone, a figure that already exceeds the top end of the old global estimate. When the rest of the world is included, the total number of survivors is estimated to be between 105,000 and 176,000.
The study also looks at the flow of new patients entering this system each year, distinguishing between babies born with the heart condition and those who successfully complete the full series of surgeries. By analyzing the birth rates of the nine specific heart defects that require this pathway, the research estimates that roughly 73,000 infants are born worldwide every year with the anatomy that makes them candidates for the Fontan procedure. Of these, about 43,000 are expected to survive the surgical journey to reach a completed Fontan circulation. This annual number of new candidates is nearly equal to the entire living population that the old 70,000 figure was supposed to represent. This comparison highlights a critical gap: the old number treated the population as a static group, failing to account for the steady stream of new patients and the fact that many more children are born with the condition than are currently counted in medical records.
The implications of this underestimation are significant. Because the population appears smaller than it really is, it is often classified as a "rare disease," which influences how drug companies and funding agencies prioritize research. If the true population is larger, the potential market for new treatments is bigger, and the need for specialized care is more urgent. The study argues that relying on an unsourced number has systematically suppressed investment in this field. By providing a transparent, reproducible method for estimating the population, the research offers a new tool for the medical community. It does not claim to have found the final, perfect answer, but it replaces a guess with a framework that can be tested and improved as more data becomes available. The goal is to ensure that the people living with this complex heart condition are finally counted correctly, so that the resources they need can be found and delivered.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.